Cyltezo®, adalimumab biosimilar from Boehringer Ingelheim, approved in Europe for the treatment of multiple chronic inflammatory diseases
● The European Commission has granted marketing authorisation for a biosimilar to Humira® for the treatment of multiple chronic inflammatory diseases

● Robust analytical, pharmacological, non–clinical & clinical data demonstrated the similarity of Cyltezo® to Humira®

● Approval follows recent positive CHMP opinion1 and FDA approval2 of Cyltezo®